Duchenne muscular dystrophy (DMD) is a genetic disease characterized by rapidly progressing weakness and degeneration of the skeletal muscles. This study presents a modeling approach using MR biomarkers to characterize disease progression in individuals with DMD receiving deflazacort, prednisone/prednisolone, or no corticosteroid treatment. The findings from a sample of convenience compiled from the ImagingDMD study demonstrate that 1) corticosteroid treatment slows DMD disease progression, with deflazacort slowing progression to a greater extent than prednisone/prednisolone, and 2) the slow-progressing muscles in DMD are more sensitive to treatment effects, and hence, could be better candidates to assess therapeutic response in clinical trials.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords